DCM
DAFNA Capital Management’s UroGen Pharma URGN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.79M | Sell |
349,515
-143,000
| -29% | -$1.96M | 1.32% | 23 |
|
|
2025
Q1 | $5.45M | Hold |
492,515
| – | – | 1.54% | 18 |
|
|
2024
Q4 | $5.25M | Buy |
492,515
+33,600
| +7% | +$358K | 1.33% | 19 |
|
|
2024
Q3 | $5.83M | Sell |
458,915
-10,085
| -2% | -$128K | 1.38% | 22 |
|
|
2024
Q2 | $7.87M | Buy |
+469,000
| New | +$7.87M | 1.88% | 20 |
|
|
2020
Q2 | – | Sell |
-2,369
| Closed | -$42K | – | 92 |
|
|
2020
Q1 | $42K | Sell |
2,369
-1,618
| -41% | -$28.7K | 0.02% | 80 |
|
|
2019
Q4 | $133K | Sell |
3,987
-11,013
| -73% | -$367K | 0.05% | 79 |
|
|
2019
Q3 | $357K | Hold |
15,000
| – | – | 0.13% | 77 |
|
|
2019
Q2 | $539K | Hold |
15,000
| – | – | 0.2% | 69 |
|
|
2019
Q1 | $554K | Hold |
15,000
| – | – | 0.24% | 65 |
|
|
2018
Q4 | $646K | Hold |
15,000
| – | – | 0.32% | 55 |
|
|
2018
Q3 | $708K | Buy |
15,000
+5,000
| +50% | +$236K | 0.29% | 57 |
|
|
2018
Q2 | $498K | Buy |
10,000
+5,500
| +122% | +$274K | 0.23% | 61 |
|
|
2018
Q1 | $224K | Buy |
+4,500
| New | +$224K | 0.11% | 68 |
|